Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based biopharmaceutical firm Kymab has secured $100m of funding to advance its pipeline of therapeutic human monoclonal antibodies.
Subscribe to our email newsletter
ORI Healthcare Fund (ORI Fund) led the Series C financing with participation by Shenzhen Hepalink Pharmaceutical (Hepalink).
Existing shareholders Wellcome Trust, Bill & Melinda Gates Foundation, Malin Corporation, CF Woodford Equity Income Fund and Woodford Patient Capital have also made follow-on investments.
The latest round follows the $120m Series A & B financings secured Kymab, which is using the Kymouse transgenic human antibody platform for the discovery and development of fully human monoclonal antibody drugs.
Kymab CEO Dave Chiswell said: "ORI Fund and Hepalink bring deep experience of the pharmaceutical industry. Hepalink has a global reach for their products and have biologics manufacturing capability in the US.
“This investment will help us maximise the potential of the Kymab pipeline as we develop and commercialise monoclonal antibody medicines for patients world-wide."
Kymab’s Kymouse platform is capable of discovering antibodies that are difficult to develop and produce. It naturally matures those molecules to highly potent drugs eliminating the need for additional time-consuming changes.
The platform is being used for Kymab’s internal drug discovery programs and in partnership with pharmaceutical firms.
Kymab, which started operations in 2010, has to date raised more than $220m of equity financing.
The company presently has 12 pre-clinical programs under development with a focus on immuno-oncology, hematology, autoimmune disease and infectious disease.
Image: Kymab secures $100m Series C funding. Photo: courtesy of Kymab.